|2.||Alzheimer Disease (Alzheimer's Disease)
|3.||Parkinson Disease (Parkinson's Disease)
|4.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
|5.||Schizophrenia (Dementia Praecox)
|1.||Zink, M Christine: 10 articles (12/2014 - 08/2003)|
|2.||Mankowski, Joseph L: 9 articles (07/2015 - 02/2003)|
|3.||Queen, Suzanne E: 8 articles (07/2015 - 02/2003)|
|4.||Vincent, Angela: 8 articles (02/2015 - 05/2003)|
|5.||Adams, Robert J: 7 articles (07/2015 - 02/2003)|
|6.||Tarwater, Patrick M: 7 articles (12/2014 - 03/2005)|
|7.||Dale, Russell C: 7 articles (07/2014 - 06/2003)|
|8.||Clements, Janice E: 6 articles (07/2015 - 08/2003)|
|9.||Dalakas, Marinos C: 5 articles (12/2015 - 05/2005)|
|10.||Niswender, Colleen M: 5 articles (11/2015 - 07/2007)|
|1.||Proteins (Proteins, Gene)IBA
11/01/2010 - "Identification of disease-associated proteins is critical for elucidating CNS disease mechanisms and elaborating novel treatment strategies. "
07/20/2012 - "These data, together with the possibility to employ nanoparticles for delivery of proteins and other macromolecules across the BBB, suggest that this technology holds great promise for non-invasive therapy of the CNS diseases."
09/10/2015 - "Proteomics is a powerful way to identifying multiple proteins which are altered following a neuropharmacological intervention in a CNS disease."
03/06/2015 - "The σ1 proteins are considered to be a new class of target structures for several central nervous system disorders, including depression, anxiety, psychosis, and Parkinson's and Alzheimer's diseases. "
03/01/2015 - "We revise here how the engineering of functional proteins offers drug delivery tools for specific CNS diseases and more transversally, how proteins can be engineered into smart nanoparticles or 'artificial viruses' to afford therapeutic requirements through alternative administration routes. "
|2.||DNA (Deoxyribonucleic Acid)IBA
01/01/2016 - "Somatic DNA Variation in Brain as a Source of Risk for CNS Diseases."
08/01/2013 - "The EBV DNA loads of CSF could act as an important indicator, but the EBV DNA loads of blood could not, for the diagnosis, prognosis, and therapeutic evaluation of EBV-associated CNS diseases."
08/01/2013 - "In 12 patients with EBV-associated CNS diseases, EBV DNA levels were declining in both blood and CSF with the control of diseases, and the EBV DNA loads of CSF decreased faster than that of blood in 5 patients who responded to treatment, and the EBV DNA levels of CSF increased in 5 patients who were unresponsive to treatment. "
08/01/2013 - "The EBV DNA loads of CSF were higher than that of blood in patients with EBV-associated CNS diseases. "
08/01/2013 - "The EBV DNA levels of CSF were monitored in patients with EBV-associated CNS diseases before the treatment and at different points following the treatment. "
|3.||rituximab (Mabthera)FDA Link
04/23/2009 - "One thousand two hundred twenty-two patients treated in the Rituximab with CHOP over age 60 years (RICOVER-60) trial were examined for central nervous system (CNS) disease developing during first-line therapy or after a complete or partial remission had been achieved. "
05/01/2012 - "Patients with aaIPI 2 or 3 showed a moderate risk (4.2%-9.7%) and no significant reduction of CNS disease with rituximab. "
08/01/2015 - "Leptomeningeal disease was more common and the survival after CNS disease was better in the rituximab era. "
07/31/2014 - "In conclusion, rituximab eliminates the increased risk for CNS disease in patients with ECFI. "
07/31/2014 - "Without rituximab, the 2-year cumulative rate of central nervous system (CNS) disease was increased in 205 ECFI patients compared with 2586 non-ECFI patients (4.2% vs 2.8%; P = .038), whereas this was not observed with rituximab (1.6% in 83 ECFI vs 3.4% in 1252 non-ECFI patients; P = .682). "
|4.||Cytarabine (Cytosar-U)FDA LinkGeneric
05/01/2002 - "In multivariate analysis, non-L2-FAB, higher ara-C dose, absence of CNS disease, non-Ph1+ karyotype, allogeneic BMT, T cell phenotype, and younger age were associated with improved disease-free survival. "
04/15/2007 - "Liposomal cytarabine 50 mg was given intrathecally on days 2 and 15 of hyper-CVAD and day 10 of high-dose MTX and cytarabine courses until completion of either 3, 6, or 10 IT treatments, depending on risk for CNS disease. "
01/01/1985 - "For established CNS disease, IT-Ara-C for three days followed by MTX on the fourth day is effective. "
10/01/1990 - "Cytarabine is effective in the treatment of leukemias and CNS disease when given SQ, IM, IV, or intrathecally. "
05/01/2015 - "It is thought that the low incidence of central nervous system (CNS) involvement in acute myeloid leukemia (AML) does not justify routine CNS prophylaxis, as high-dose cytarabine eliminates CNS disease. "
01/01/2003 - "Subclinical central nervous system (CNS) disease in NLE is likely to be a transient phenomenon that resolves as maternal antibodies are cleared from the infant's circulation. "
05/01/2009 - "Based on this study, these bacteria are unlikely causes of neurologic disease in dogs and the presence of serum antibodies alone does not document or establish a definitive diagnosis of CNS disease caused by these organisms. "
01/01/2003 - "This evidence consists of 1) seven independent studies showing a strong relationship between anti-P antibodies and CNS disease; 2) longitudinal studies showing fluctuations of anti-P antibodies with episodes of psychosis; 3) correlation of anti-P antibodies with general disease activity; and 4) acid eluates form lupus renal tissue were found to contain anti-P antibodies enriched 30-fold with respect to their specific activity in serum heralding a direct role of anti-P antibodies in disease expression. "
08/01/1993 - "This study examines the spectrum of psychiatric and cognitive dysfunction observed in SS patients with focal, as well as nonfocal, central nervous system (CNS) disease and relates these observations to the presence of serum and cerebrospinal fluid (CSF) anti-ribosomal and anti-neuronal antibodies. "
12/15/2015 - "It is unclear why the anti-AQP4 antibodies did not induce CNS disease. "
01/01/2003 - "Continued study will inform us of the relative contribution of these autoantibodies to CNS disease in SLE patients."
02/01/2013 - "There is increasing interest in the role of autoantibodies in acquired autoimmune central nervous system disorders. "
06/01/2012 - "In the present report, we evaluated the autoantibodies against transglutaminase2 (TG2) in the canine CNS diseases. "
05/01/2008 - "[Which role of antineural autoantibodies in central nervous system diseases?]."
08/01/2005 - "Moreover, chronic inflammatory CNS disease may induce autoantibodies by virtue of epitope spreading."
02/25/2015 - "Fully exploring the polarization status of microglia during CNS diseases and the role of miRNAs in microglia polarization will be very helpful for a deep understanding of the roles of microglia in immunopathologic mechanism of different CNS diseases and offer the theoretical foundation of searching more effective therapies for these disorders. "
08/20/2014 - "This compound is also able to modulate various microRNA, an interesting result in light of the recent view that modulation of microRNAs may be useful for the treatment of CNS disease. "
02/25/2015 - "MiRNAs regulate microglia polarization, and thus affect the progress of CNS diseases. "
02/25/2015 - "[MicroRNAs in microglia polarization and CNS diseases: mechanism and functions]."
01/01/2015 - "miRNAs and SAMHD1 regulation in vitro and in a model of HIV CNS disease."
|8.||trastuzumab (Herceptin)FDA Link
03/01/2012 - "This phenomenon likely reflects the difficult CNS drug-penetration and improved control of extra-CNS disease following the clinical use of the anti-HER2 monoclonal antibody trastuzumab. "
05/01/2010 - "A wealth of data from clinical studies showed that trastuzumab prolonged survival in patients with mCNS disease, compared with no trastuzumab treatment, by effectively controlling their non-CNS disease. "
01/01/2015 - "Due to progressive CNS disease, intrathecal (IT) trastuzumab was introduced to enhance HER-2+ therapy into the CSF space. "
06/01/2013 - "Central nervous system (CNS) disease as the site of first relapse after exposure to adjuvant trastuzumab has been reported. "
05/01/2011 - "Improvements in systemic control and overall survival associated with trastuzumab-based therapy may lead to an "unmasking" of CNS disease recurrence that would otherwise remain clinically silent before a patient's death."
|9.||Ganciclovir (Cytovene)FDA LinkGeneric
06/01/1996 - "Ganciclovir-resistant CMV, containing a UL97 mutation, was cultured from blood and urine before clinical indication of CMV central nervous system (CNS) disease, suggesting that the development of ganciclovir resistance preceded the dissemination of CMV to the CNS. "
11/01/1995 - "The CSF of all seven patients who had not received ganciclovir prior to the development of CNS disease and four patients who had been receiving the drug for 3 to 8 months contained wild-type UL97 sequences. "
11/01/1995 - "These findings indicate that CNS disease in AIDS patients receiving prolonged ganciclovir therapy can be caused by ganciclovir-resistant HCMV strains. "
06/01/2004 - "Although ganciclovir is unlikely to be effective against HHV-7-related CNS disease, foscarnet may be useful but prospective trials are needed."
01/01/1995 - "Ganciclovir treatment of 3 patients with HCMV-related CNS disease was associated with a decline in HCMV DNA detectable within CSF. "
|10.||Acyclovir (Aciclovir)FDA LinkGeneric
09/01/2014 - "Treatment of affected neonates with intravenous acyclovir has improved outcomes but there is room for further improvement, especially in regard to CNS disease. "
10/01/2013 - "All patients received acyclovir treatment, although substantial numbers of patients in severe clinical categories (disseminated or central nervous system diseases) received a low dose of acyclovir (<60 mg/kg per day). "
04/01/2003 - "Efforts made during the past decade to improve the outcome of HSV CNS disease have focused on increased doses of intravenous acyclovir administered for longer durations of time. "
03/01/1999 - "Prophylaxis with acyclovir did not prevent the occurrence of HHV-6-associated CNS disease after allogeneic bone marrow transplantation. "
01/01/2009 - "One study treated 63 infants with vidarabine or placebo (Whitley 1980) and the other study treated 210 infants with aciclovir or vidarabine (Whitley 1991).In the study comparing vidarabine with placebo (Whitley 1980), infants with all forms of neonatal HSV disease were included [disseminated disease, central nervous system (CNS) disease alone, and skin, eye and mouth (SEM) disease].There was no significant reduction in the risk of mortality when analyzed as an entire group; however, mortality was significantly reduced when data from infants with CNS disease or disseminated disease were combined. "
|1.||Drug Therapy (Chemotherapy)
07/01/2015 - "She was treated with recommended DeAngelis protocol for PCNSL and achieved complete remission of CNS disease and in the right eye and responded only partially to the systemic chemotherapy in the left eye. "
01/01/2015 - "Therefore, the dose of MTX or interval of each chemotherapy cycle should be modified in future trials to control CNS disease involved with DLBCL."
05/01/2014 - "There was no consistent evidence from the randomized trials currently available for an additional risk of HIV CNS disease during monotherapy with either LPV/r or DRV/r versus standard triple drug therapy. "
03/01/1997 - "Recommendations of the "CNS Diseases" Study Group of the Paul Ehrlich Society of Chemotherapy e.V. and the German Society of Pediatric Infectiology]."
10/01/2015 - "Hence, the greatest challenge in the pharmacotherapy of CNS diseases is to ensure efficient brain targeting and drug delivery. "
|2.||Transplantation (Transplant Recipients)
07/01/2014 - "Univariate analysis demonstrated that African American race, high initial white blood cell count, central nervous system (CNS) disease at diagnosis, short first complete remission, nonmyeloablative (NMA) conditioning, lack of remission, and MRD before transplantation were associated with worse relapse-free survival (RFS). "
01/01/2015 - "Therefore, BMSC transplantation may be effective for the treatment of central nervous system disorders. "
04/01/2009 - "Mesenchymal stem cell (MSC) transplantation is a promising approach in the therapy of ischemic heart or CNS diseases; however, the poor viability of MSCs after transplantation critically limits the efficacy of this new strategy. "
03/01/2010 - "Clinical studies have expanded the therapeutic olfactory ensheathing cells (OECs) transplantation to different human Central Nervous System (CNS) diseases. "
01/01/2009 - "Between November 2001 and January 2008, 1,255 participants with central nervous system diseases were enrolled in this clinical study for fetal OECs transplantation. "
|3.||Traditional Medicine (Folk Remedies)
08/01/2005 - "Galphimia glauca has been used in Mexican traditional medicine as a remedy for the treatment of nervous excitement and other central nervous system disorders. "
11/20/2008 - "Tagetes lucida (Asteraceae), has been referred in Mexican traditional medicine for the treatment of different central nervous system (CNS) diseases, mainly depression. "
08/11/2006 - "Salvia elegans Vahl (Lamiaceae), popularly known as "mirto", is a shrub that has been widely used in Mexican traditional medicine for the treatment of different central nervous system (CNS) diseases, principally, anxiety. "
06/01/2014 - "In Iranian traditional medicine, physicians such as Avicenna were prescribing herbal drugs through the nose to treat a variety of central nervous system diseases like headache. "
03/01/2014 - "pluricaulis has emerged as a good source of the traditional medicine for the treatment of liver disease, epileptic disease, microbial disease, cytotoxic and viral diseases, and CNS disease. "
12/10/2015 - "FUS mediated BBB disruption has the potential to fundamentally change how CNS diseases are treated, unlocking potential for combinatorial treatments with nanotechnology, markedly increasing the efficacy of existing therapeutics that otherwise do not cross the BBB effectively, and permitting safe repeated treatments. "
12/01/2014 - "Studies aimed at advancing our understanding of CNS diseases and promoting the development of more effective therapeutics are primarily performed in laboratory animals. "
05/26/2011 - "Since their discovery twenty years ago and prospective isolation a decade later, neural stem cells (NSCs), their progenitors, and differentiated cell derivatives along with other stem-cell based strategies have advanced steadily toward clinical trials, spurred by the immense need to find reparative therapeutics for central nervous system (CNS) diseases and injury. "
09/01/2004 - "CNS diseases congress: advances in therapeutics, tools and trials. "
11/01/2015 - "Phosphodiesterase-9 (PDE9) inhibitors have been studied as potential therapeutics for treatment of central nervous system diseases and diabetes. "
08/01/1984 - "Survival after relapse ranged from 11 to 476 weeks (median 92); seven patients are alive; four in continued remission, two with recurrent but controlled CNS disease, and one in remission following bone marrow transplant after subsequent marrow relapse. "
10/01/2011 - "Although our data suggest that allo-HSCT is a therapeutic option for ATL with CNS disease, high transplant-related mortality (six cases) indicates the need for further studies to develop more effective procedures for CNS disease, and to reduce transplant-related morbidity."
06/01/2005 - "Thus, the results of this study support the possible use of autologous-cell graft systems to treat central nervous system diseases in geriatric patients."
08/01/2013 - "Post-transplant EBV-associated diseases developed in 27 patients, including 12 patients with EBV-associated CNS diseases. "
07/15/2012 - "Treatment of recurrent CNS disease post-bone marrow transplant in familial HLH."